NNZ-2566 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Injuries
Conditions
Brain Injuries
Trial Timeline
Apr 1, 2010 → Jan 1, 2016
NCT ID
NCT00805818About NNZ-2566 + Placebo
NNZ-2566 + Placebo is a phase 2 stage product being developed by Neuren Pharmaceuticals for Brain Injuries. The current trial status is completed. This product is registered under clinical trial identifier NCT00805818. Target conditions include Brain Injuries.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02715115 | Phase 2 | Completed |
| NCT02100150 | Phase 2 | Terminated |
| NCT01894958 | Phase 2 | Completed |
| NCT01703533 | Phase 2 | Completed |
| NCT01366820 | Phase 2 | Completed |
| NCT01420042 | Phase 1 | Completed |
| NCT00805818 | Phase 2 | Completed |
| NCT00961779 | Phase 1 | Completed |
Competing Products
20 competing products in Brain Injuries
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 52 |
| GLIADEL | Eisai | Phase 2 | 52 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 33 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| ABT-888 | AbbVie | Phase 1 | 33 |
| Veliparib + Placebo | AbbVie | Phase 2 | 52 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 52 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 52 |
| Exenatide | AstraZeneca | Approved | 85 |
| AZD5213 | AstraZeneca | Phase 1 | 33 |